Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of SporeGen.

    Client Virtual Booth

    SPOREGEN

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    SporeGen
    unitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    The London BioScience Innovation Centre 2 Royal College Street Camden Town, London, NW1 0NH
    Telephone
    Telephone
    +44-(0)1784-443760
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://sporegen.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Destiny Pharma and SporeGen® Announce Update from Research Collaboration Under Innovate UK Grant Award to Develop a Biotherapeutic Treatment (SPOR-COVÂ...

    Details:

    SPOR COV product consists of a proprietary formulation of Bacillus bacteria that is administered nasally as a spray. It is being developed for for COVID-19 and Influenza.


    Lead Product(s): Bacillus Bacteria

    Therapeutic Area: Infections and Infectious Diseases Product Name: SPOR-COV

    Highest Development Status: PreclinicalProduct Type: Vaccine

    Recipient: Destiny Pharma

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 02, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    SporeGen® Announces Collaboration with Destiny Pharma Supported by an Innovate UK grant award for a Preventative Treatment for COVID-19

    Details:

    Under the agreement, the parties will share any costs and commercial returns from SPOR-COV and plan to complete a pre-clinical programme with the aim of being ready to enter the first human clinical trials within 18 months.


    Lead Product(s): SPOR-COV

    Therapeutic Area: Infections and Infectious Diseases Product Name: SPOR-COV

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Recipient: Destiny Pharma

    Deal Size: $1.0 million Upfront Cash: Undisclosed

    Deal Type: Collaboration September 08, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search